Sugi Predict

Sugi Predict / Compounds / SCHEMBL9986171

SCHEMBL9986171

SCHEMBL9986171

[C-]#[N+]C(c1ccc(Cl)c(Cl)c1)S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ALKBH3 Q96Q83 1/20 0.38
▸ SLC6A2 P23975 2/20 0.36
▸ SLC6A4 P31645 2/20 0.36
▸ SLC6A3 Q01959 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ PTGS2 P35354 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ MGAM O43451 1/20 0.35
▸ SI P14410 1/20 0.35
▸ MGAM2 Q2M2H8 1/20 0.35
▸ BCHE P06276 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ S1PR2 O95136 1/20 0.34
▸ S1PR4 O95977 1/20 0.34
▸ S1PR1 P21453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653976 0.87 PTGS2 (0.41) MEN1KMT2ALMNAPTGS2
SCHEMBL30716683 0.87 PTGS2 (0.41) MEN1KMT2ALMNAPTGS2
SCHEMBL29956006 0.84 GAA (0.45) MAPTALDH1A1LMNAGAABCHE
SCHEMBL29954990 0.83 GAA (0.38) ALDH1A1LMNAGAABCHEACHE
SCHEMBL29956135 0.83 UTS2R (0.43) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL29952039 0.81 MAPT (0.44) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL5851624 0.81 MAPT (0.44) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL5852069 0.79 PTGS2 (0.41) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL29955568 0.79 PTGS2 (0.41) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL29957269 0.79 CA1 (0.37) MAPTMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-20130211079-A1 SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER DOEMLING ALEXANDER (US) 2013-08-15 — — US disclosed
US-20130211079-A1 SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER DOEMLING ALEXANDER (US) 2013-08-15 — — US disclosed
US-20110313167-A1 Substituted Heterocycles as Therapeutic agents for treating cancer UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2011-12-22 — — US disclosed
US-20110313167-A1 Substituted Heterocycles as Therapeutic agents for treating cancer UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2011-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313167-A1 Substituted Heterocycles as Therapeutic agents for treating cancer TP53, MDM4, MDM2 MAPT 2547/4885MEN1 941/4885KMT2A 2492/4885
US-20130211079-A1 SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER TP53, MDM4, MDM2 MAPT 2547/4885MEN1 941/4885KMT2A 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.